<DOC>
	<DOC>NCT02202356</DOC>
	<brief_summary>This study will assess the safety, tolerability, pharmacokinetics (PK) and anti-viral effect of single and multiple doses of ALS-008176 in infants hospitalized with respiratory syncytial virus (RSV)</brief_summary>
	<brief_title>A Study of ALS-008176 in Infants Hospitalized With RSV</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>Male or female infant who is ≥1.0 to ≤12.0 months of age (inclusive), defined at the time of hospital admission, or &lt;28 days of age (neonate cohort only). Note: all subjects, including neonates, must have been discharged from the hospital after birth and are now being admitted due to an RSV related illness Prematurity Receiving invasive endotracheal mechanical ventilation Poorly functioning gastrointestinal tract Anticipated to be discharged from the hospital in &lt;24 hours from the time of randomization Prior exposure to palivizumab</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>RSV</keyword>
	<keyword>Respiratory Syncytial Virus</keyword>
</DOC>